Home>
US Stocks>
Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc (ARCT) live share price

Arcturus Therapeutics Holdings Inc share price in USD $18.34 & INR ₹1,553.31

$18.34

▲

0.83

(4.74%)

View live Arcturus Therapeutics Holdings Inc share price in Dollar and Rupees. Guide to invest in Arcturus Therapeutics Holdings Inc from India. Also see the sentimental analysis on Indian investors investing in Arcturus Therapeutics Holdings Inc. Get details on the Indian mutual funds that are investing in Arcturus Therapeutics Holdings Inc. Get Analyst recommendations and forecasts along with all the Arcturus Therapeutics Holdings Inc's financials.

Arcturus Therapeutics Holdings Inc share price movements

$17.63
$18.62
$18.34
3.87%
Downside
Day's Volatility :5.29%
Upside
1.48%
$14.93
$45.00
$18.34
18.59%
Downside
52 Weeks Volatility :66.82%
Upside
59.24%

Arcturus Therapeutics Holdings Inc Returns

Period	Arcturus Therapeutics Holdings Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-5.42%	-6.2%	0.0%
6 Months	-54.89%	2.6%	0.0%
1 Year	-23.55%	11.8%	0.0%
3 Years	-50.45%	13.3%	-19.8%

Arcturus Therapeutics Holdings Inc Key Statistics

in dollars & INR

Market Capitalization	$496.8M
Revenue TTM	$160.4M
EBITDA	$-77.0M
Earnings Per Share (EPS)	$-2.33
Profit Margin	-39.05%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-23.12%

How to invest in Arcturus Therapeutics Holdings Inc from India?

It is very easy for Indian residents to invest directly in Arcturus Therapeutics Holdings Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Arcturus Therapeutics Holdings Inc stock in both rupees (INR) and dollars (USD). Search for Arcturus Therapeutics Holdings Inc or ARCT on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Arcturus Therapeutics Holdings Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Arcturus Therapeutics Holdings Inc shares which would translate to 0.046 fractional shares of Arcturus Therapeutics Holdings Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Arcturus Therapeutics Holdings Inc

113%

Period: Sep 2, 2024 to Dec 1, 2024. Change in 30 Days versus previous period

Search volume for Arcturus Therapeutics Holdings Inc on INDmoney from India has grown in the last 30 days as on Dec 2, 2024. 113% more investors are searching Arcturus Therapeutics Holdings Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Arcturus Therapeutics Holdings Inc

Federated Hermes Inc
17.33%
BlackRock Inc
9.78%
Sumitomo Mitsui Trust Group Inc
8.40%
ARK Investment Management LLC
7.76%
Morgan Stanley - Brokerage Accounts
5.88%
Vanguard Group Inc
5.82%

Analyst Recommendation on Arcturus Therapeutics Holdings Inc

Buy

87%Buy

6%Hold

6%Sell

Based on 16 Wall street analysts offering stock ratings for Arcturus Therapeutics Holdings Inc(by analysts ranked 0 to 5 stars)

Based on 16 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Arcturus Therapeutics Holdings Inc

What analysts predicted

Upside of 333.3%

Current:

$18.34

Target:

$79.47

Insights on Arcturus Therapeutics Holdings Inc

Decreasing Revenue
Revenue is down for the last 2 quarters, 45.97M → 41.67M (in $), with an average decrease of 9.4% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -26.81M → -6.90M (in $), with an average increase of 102.6% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 47.6% return, outperforming this stock by 73.9%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.4% return, outperforming this stock by 89.8%

Arcturus Therapeutics Holdings Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$15.8M	↑ 21.2%
Net Income	$-21.8M	↑ 99.83%
Net Profit Margin	-138.29%	↓ 54.42%

	FY19	Y/Y Change
Revenue	$20.8M	↑ 31.97%
Net Income	$-25.7M	↑ 18.07%
Net Profit Margin	-123.72%	↑ 14.57%

	FY20	Y/Y Change
Revenue	$9.5M	↓ 54.12%
Net Income	$-71.4M	↑ 177.45%
Net Profit Margin	-748.13%	↓ 624.41%

	FY21	Y/Y Change
Revenue	$12.4M	↑ 29.56%
Net Income	$-206.9M	↑ 189.87%
Net Profit Margin	-1.7K%	↓ 925.65%

	FY22	Y/Y Change
Revenue	$205.8M	↑ 1564.82%
Net Income	$9.3M	↓ 104.52%
Net Profit Margin	4.54%	↑ 1678.32%

	FY23	Y/Y Change
Revenue	$157.7M	↓ 23.33%
Net Income	$-29.7M	↓ 417.95%
Net Profit Margin	-18.84%	↓ 23.38%

	Q2 FY23	Q/Q Change
Revenue	$9.6M	↓ 88.0%
Net Income	$-52.6M	↓ 203.54%
Net Profit Margin	-549.4%	↓ 613.06%

	Q3 FY23	Q/Q Change
Revenue	$43.4M	↑ 353.49%
Net Income	$-16.2M	↓ 69.13%
Net Profit Margin	-37.4%	↑ 512.0%

	Q4 FY23	Q/Q Change
Revenue	$28.2M	↓ 34.96%
Net Income	$-8.6M	↓ 47.15%
Net Profit Margin	-30.39%	↑ 7.01%

	Q1 FY24	Q/Q Change
Revenue	$32.6M	↑ 15.55%
Net Income	$-26.8M	↑ 212.81%
Net Profit Margin	-82.27%	↓ 51.88%

	Q2 FY24	Q/Q Change
Revenue	$46.0M	↑ 41.04%
Net Income	$-17.2M	↓ 35.8%
Net Profit Margin	-37.45%	↑ 44.82%

	Q3 FY24	Q/Q Change
Revenue	$41.7M	↓ 9.36%
Net Income	$-6.9M	↓ 59.9%
Net Profit Margin	-16.56%	↑ 20.89%

	FY18	Y/Y Change
Total Assets	$44.2M	↓ 15.04%
Total Liabilities	$30.6M	↑ 67.61%

	FY19	Y/Y Change
Total Assets	$82.1M	↑ 85.85%
Total Liabilities	$56.4M	↑ 84.42%

	FY20	Y/Y Change
Total Assets	$476.5M	↑ 480.03%
Total Liabilities	$79.9M	↑ 41.8%

	FY21	Y/Y Change
Total Assets	$392.8M	↓ 17.56%
Total Liabilities	$164.6M	↑ 106.0%

	FY22	Y/Y Change
Total Assets	$450.4M	↑ 14.66%
Total Liabilities	$180.1M	↑ 9.4%

	FY23	Y/Y Change
Total Assets	$429.4M	↓ 4.66%
Total Liabilities	$150.9M	↓ 16.21%

	Q2 FY23	Q/Q Change
Total Assets	$430.6M	↓ 8.54%
Total Liabilities	$145.5M	↑ 2.72%

	Q3 FY23	Q/Q Change
Total Assets	$457.7M	↑ 6.27%
Total Liabilities	$177.6M	↑ 22.08%

	Q4 FY23	Q/Q Change
Total Assets	$429.4M	↓ 6.17%
Total Liabilities	$150.9M	↓ 15.03%

	Q1 FY24	Q/Q Change
Total Assets	$418.8M	↓ 2.46%
Total Liabilities	$154.9M	↑ 2.64%

	Q2 FY24	Q/Q Change
Total Assets	$388.6M	↓ 7.22%
Total Liabilities	$130.0M	↓ 16.05%

	Q3 FY24	Q/Q Change
Total Assets	$370.7M	↓ 4.62%
Total Liabilities	$108.8M	↓ 16.33%

	FY18	Y/Y Change
Operating Cash Flow	$-20.8M	↑ 4413.04%
Investing Cash Flow	$22.1M	↑ 113.75%
Financing Cash Flow	$10.2M	↑ 45.81%

	FY19	Y/Y Change
Operating Cash Flow	$-6.4M	↓ 68.95%
Investing Cash Flow	$-818.0K	↓ 103.7%
Financing Cash Flow	$41.9M	↑ 310.69%

	FY20	Y/Y Change
Operating Cash Flow	$-42.9M	↑ 565.03%
Investing Cash Flow	$-1.7M	↑ 112.96%
Financing Cash Flow	$436.1M	↑ 940.74%

	FY21	Y/Y Change
Operating Cash Flow	$-135.0M	↑ 215.07%
Investing Cash Flow	$-3.4M	↑ 95.52%
Financing Cash Flow	$48.0M	↓ 88.99%

	FY22	Y/Y Change
Operating Cash Flow	$32.0M	↓ 123.69%
Investing Cash Flow	$-7.7M	↑ 126.83%
Financing Cash Flow	$-2.9M	↓ 105.95%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$50.8M	↓ 241.64%
Investing Cash Flow	$-354.0K	↓ 48.77%
Financing Cash Flow	$94.0K	↓ 100.34%

Arcturus Therapeutics Holdings Inc Technicals Summary

Sell

Neutral

Buy

Arcturus Therapeutics Holdings Inc is currently in a neutral trading position according to technical analysis indicators.

Arcturus Therapeutics Holdings Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Arcturus Therapeutics Holdings Inc	2.92%	-54.89%	-23.55%	-50.45%	81.23%
Regeneron Pharmaceuticals, Inc.	-9.49%	-24.18%	-8.88%	18.12%	102.78%
Biontech Se	8.64%	15.09%	18.5%	-65.59%	454.0%
Alnylam Pharmaceuticals, Inc.	-6.25%	68.21%	46.39%	47.68%	107.47%
Vertex Pharmaceuticals Incorporated	-0.99%	-0.44%	33.51%	129.69%	109.07%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Arcturus Therapeutics Holdings Inc	10.3	NA	NA	-2.39	-0.23	-0.12	NA	9.67
Regeneron Pharmaceuticals, Inc.	18.66	18.66	1.12	44.91	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.22	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Arcturus Therapeutics Holdings Inc	Buy	$496.8M	81.23%	10.3	-39.05%
Regeneron Pharmaceuticals, Inc.	Buy	$83.0B	102.78%	18.66	33.61%
Biontech Se	Buy	$28.9B	454.0%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	107.47%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$119.6B	109.07%	32.84	-4.51%

About Arcturus Therapeutics Holdings Inc

founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.

Organization	Arcturus Therapeutics Holdings Inc
Employees	180
CEO	Mr. Joseph E. Payne M.Sc.
Industry	Health Technology

Important FAQs about investing in Arcturus Therapeutics Holdings Inc from India :

What is Arcturus Therapeutics Holdings Inc share price today?

Arcturus Therapeutics Holdings Inc (ARCT) share price today is $18.34.

Can Indians buy Arcturus Therapeutics Holdings Inc shares?

Yes, Indians can invest in the Arcturus Therapeutics Holdings Inc (ARCT) from India.

With INDmoney, you can buy Arcturus Therapeutics Holdings Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Arcturus Therapeutics Holdings Inc at zero transaction cost.

How can I buy Arcturus Therapeutics Holdings Inc shares from India?

It is very easy to buy Arcturus Therapeutics Holdings Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Arcturus Therapeutics Holdings Inc be purchased?

Yes, you can buy fractional shares of Arcturus Therapeutics Holdings Inc with INDmoney app.

What are the documents required to start investing in Arcturus Therapeutics Holdings Inc stocks?

To start investing in Arcturus Therapeutics Holdings Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Arcturus Therapeutics Holdings Inc

Today’s highest price of Arcturus Therapeutics Holdings Inc (ARCT) is $18.62.

Today’s lowest price of Arcturus Therapeutics Holdings Inc (ARCT) is $17.63.

What is today's market capitalisation of Arcturus Therapeutics Holdings Inc

Today's market capitalisation of Arcturus Therapeutics Holdings Inc ARCT is 496.8M

What is the 52 Week High and Low Range of Arcturus Therapeutics Holdings Inc

52 Week High
$45.00
52 Week Low
$14.93

How much percentage Arcturus Therapeutics Holdings Inc is down from its 52 Week High?

Arcturus Therapeutics Holdings Inc (ARCT) share price is $18.34. It is down by 99% from its 52 Week High price of $45.00.

How much percentage Arcturus Therapeutics Holdings Inc is up from its 52 Week low?

Arcturus Therapeutics Holdings Inc (ARCT) share price is $18.34. It is up by 1% from its 52 Week Low price of $14.93.

What are the historical returns of Arcturus Therapeutics Holdings Inc?

1 Month Returns
2.92%
3 Months Returns
-54.89%
1 Year Returns
-23.55%
5 Years Returns
81.23%

Who is the Chief Executive Officer (CEO) of Arcturus Therapeutics Holdings Inc

Mr. Joseph E. Payne M.Sc. is the current Chief Executive Officer (CEO) of Arcturus Therapeutics Holdings Inc.

Discover More

Explore all